NEW YORK, March 15, 2021 /PRNewswire/ -- Biotech
Acquisition Company (NASDAQ: BIOTU) (the "Company") announced that,
commencing March 18, 2021, holders of
the units sold in the Company's initial public offering may elect
to separately trade the Company's Class A ordinary shares
("Class A Ordinary Shares") and warrants included in the units. No
fractional warrants will be issued upon separation of the units and
only whole warrants will trade. The Class A Ordinary Shares and
warrants that are separated will trade on the NASDAQ Capital Market
under the symbols "BIOT" and "BIOTW," respectively. Those units not
separated will continue to trade on the NASDAQ Capital Market under
the symbol "BIOTU." Holders of the units will need to have their
brokers contact Continental Stock Transfer & Trust Company, the
Company's transfer agent, in order to separate their units into
Class A Ordinary Shares and Warrants.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities of the Company, nor
shall there be any sale of securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful.
About Biotech Acquisition Company
Biotech Acquisition Company is a blank check company formed for
the purpose of effecting a merger, amalgamation, share exchange,
asset acquisition, share purchase, reorganization or other similar
business combination with one or more businesses. Although the
Company may pursue a business target in any industry or
geographic location, the Company intends to focus its search for a
target business in the healthcare sector. The Company believes that
this focus will complement its sponsor's and management team's
backgrounds as affiliates of SPRIM Global Investments, a leading
investment firm in the life sciences and healthcare industries.
Forward-Looking Statements
This communication, and oral and written statements made from
time to time by the Company and its may include, "forward-looking
statements" within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Statements regarding
possible business combinations and the financing thereof, and
related matters, as well as all other statements other than
statements of historical fact, are forward-looking statements. Such
forward-looking statements are based on the beliefs of management,
as well as assumptions made by, and information currently available
to, the Company. Actual results could differ materially from those
contemplated by these forward-looking statements, including as a
result of certain risk factors detailed in the Company's filings
with the U.S. Securities and Exchange Commission. The Company
undertakes no obligation to update these statements after the date
hereof, except as required by law.
View original
content:http://www.prnewswire.com/news-releases/biotech-acquisition-company-announces-separate-trading-of-its-class-a-ordinary-shares-and-warrants-commencing-march-18-2021-301246706.html
SOURCE Biotech Acquisition Company